aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen

aTyr Pharma (NASDAQ:ATYR) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

ATYR has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of aTyr Pharma in a research report on Monday, December 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of aTyr Pharma in a report on Friday, March 6th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $25.67.

aTyr Pharma Trading Down 2.0%

Shares of ATYR opened at $0.85 on Friday. The company’s 50 day simple moving average is $0.85 and its 200-day simple moving average is $1.26. The firm has a market cap of $83.34 million, a PE ratio of -1.08 and a beta of 0.55. aTyr Pharma has a 12-month low of $0.64 and a 12-month high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last announced its earnings results on Thursday, March 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. As a group, equities research analysts forecast that aTyr Pharma will post -0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. UBS Group AG increased its stake in aTyr Pharma by 158.1% in the 3rd quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock valued at $3,249,000 after buying an additional 2,760,238 shares during the period. GSA Capital Partners LLP lifted its stake in shares of aTyr Pharma by 272.2% in the 4th quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock worth $2,060,000 after acquiring an additional 1,923,907 shares during the period. Millennium Management LLC boosted its holdings in shares of aTyr Pharma by 334.5% in the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock valued at $4,829,000 after acquiring an additional 1,231,052 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of aTyr Pharma by 126.1% in the second quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company’s stock valued at $10,639,000 after acquiring an additional 1,170,276 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of aTyr Pharma by 21.0% during the third quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock worth $4,060,000 after acquiring an additional 975,887 shares during the period. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.